CAR-T cell therapy is an immunotherapy that drastically improves T cell cytotoxic activity by genetically engineering T cells with receptors against an antigen specific to cancer cells without requiring MHC peptide presentation [23–26]. This evidence concerns the gene HLA-C and cancer.